{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"VHL is a tumor suppressor involved in protein degradation. Germline mutations of VHL are associated with Von Hippel-Lindau syndrome and predispose to renal cell carcinoma.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"05/05/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "21386872",
        "12004076",
        "12050673",
        "22825683"
      ]
    },
    "description":"Truncating mutations of VHL lead to the formation of several C-terminally truncated protein forms and have been detected in patients with sporadic renal cell carcinoma (PMID: 22825683). These alterations have been demonstrated to disrupt the interaction between VHL and HIF (PMID: 12050673, 12004076). Loss of VHL leads to inappropriate activation of HIF downstream target genes, thus promoting tumorigenesis in normoxic conditions (PMID: 21386872).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"R161*",
    "alterationType":null,
    "consequence":"stop_gained",
    "entrezGeneId":7428,
    "hgvs":null,
    "hugoSymbol":"VHL",
    "id":null,
    "proteinEnd":161,
    "proteinStart":161,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The VHL R161* mutation is likely oncogenic.",
  "vus":false
}